MK2 mRNA expression was significantly higher in lower-grade gliomas (LGG) and glioblastomas (GBM) compared to the expression in normal brain tissue (Figure 1A and Supplementary Figure S1A). This evidence concerns the gene MAPKAPK2 and central nervous system cancer.